Research.Patient.info
Advanced non‑small cell lung cancer (NSCLC) research hub
2 indexed studies · 1 currently recruiting
- authorisedTherapeutic confirmatory (Phase III)
IFEM – Pembrolizumab monotherapy versus pembrolizumab in combination with chemotherapy as first line therapy in females with advanced Non-small cell lung cancer (NSCLC) & PD-L1 expression ≥ 50%
This study is looking at the best first treatment for women with advanced non-small cell lung cancer that has high levels of a protein called PD-L1. It compares having an immunotherapy drug called pembrolizumab on its own against having pembrolizumab combined with standard chemotherapy.
Germany - recruitingPHASE2
Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers
This study aims to understand why some cancer treatments, called ADCs, stop working. By looking at samples from patients with advanced breast, stomach, bladder, or lung cancer, researchers hope to find better ways to choose the right ADC for each person and reduce side effects.
France